Alpha Satellite 12 Plus for CLL
Trisomy 12 is a recurrent abnormality in CLL, seen in 20% of cases1 and often appears as the unique cytogenetic aberration (40-60% of cases with trisomy 12)2.
Patients with trisomy 12 are classified as low-risk in the absence of any other genetic lesions3.
This product has been optimised for overnight hybridisation and is also available as part of the CLL Plus Screening Panel (LPH 087).
1. Swerdlow et al., editors, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, France, IARC:2008
2. Puiggros et al., Biomed Res Int 2014;1-13
3. Rossi et al., Blood 2013;121(8):1403-1412
- Area of Interest*
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.